SCHEMBL5025129

SCHEMBL5025129

CCOC(=O)C1CCN(c2nc(Cl)c(C(=O)O)cc2F)CC1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.57
SHMT2 P34897 1/20 0.51
ALDH1A1 P00352 8/20 0.50
KDM4E B2RXH2 6/20 0.50
KMT2A Q03164 4/20 0.50
MEN1 O00255 3/20 0.50
LMNA P02545 1/20 0.50
TP53 P04637 1/20 0.47
RAB9A P51151 1/20 0.47
SMN1; SMN2 Q16637 4/20 0.47
TSHR P16473 3/20 0.47
POLB P06746 2/20 0.47
MAPK1 P28482 2/20 0.46
CYP2C19 P33261 1/20 0.46
HSD17B10 Q99714 2/20 0.46
ALOX12 P18054 1/20 0.46
TDP1 Q9NUW8 2/20 0.45
HTT P42858 2/20 0.44
GAA P10253 1/20 0.44
HPGD P15428 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4170972 0.83 MAPT (0.48) MAPTALDH1A1KDM4EKMT2AMEN1
SCHEMBL20565594 0.82 ALDH1A1 (0.56) MAPTALDH1A1KDM4EKMT2AMEN1
SCHEMBL31297178 0.79 SHMT2 (0.59) MAPTSHMT2ALDH1A1KDM4EKMT2A
SCHEMBL5025161 0.78 MAPT (0.51) MAPTSHMT2ALDH1A1KDM4EKMT2A
SCHEMBL6800240 0.77 L3MBTL1 (0.52) MAPTALDH1A1KDM4EKMT2AMEN1
SCHEMBL5022271 0.77 ALDH1A1 (0.56) MAPTSHMT2ALDH1A1KDM4EKMT2A
SCHEMBL13125313 0.76 TSHR (0.53) MAPTALDH1A1KDM4EKMT2AMEN1
SCHEMBL4994166 0.75 MAPT (0.43) MAPTSHMT2ALDH1A1KDM4EKMT2A
SCHEMBL873632 0.75 MAPT (0.58) MAPTALDH1A1KDM4EKMT2AMEN1
SCHEMBL6795770 0.75 MEN1 (0.53) MAPTALDH1A1KDM4EKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7361658-B2 1-{3-chloro-5-[(4-(4-chlorothiophen-2-yl)-5-{[cyclobutyl(methyl)amino]methyl}thiazol-2-yl)carbamoyl]-2-pyridyl)piperidine-4-carboxylic acid; non-peptide thrombopoietin receptor (c-mpl-Ba/F3) ligand; less immunogenicity; platelet activator based on megakaryocyte colony; thrombocytopenia; orally ASTELLAS PHARMA INC. (JP) 2008-04-22 US disclosed
US-20060194844-A1 2-Acylaminothiazole derivative or salt thereof ASTELLAS PHARMA INC. (JP) 2006-08-31 US disclosed
EP-1647553-A1 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF Astellas Pharma Inc. (JP) 2006-04-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060194844-A1 2-Acylaminothiazole derivative or salt thereof MPL, JAK2, MATK MAPT 4790/4885SHMT2 2746/4885ALDH1A1 2150/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.